GlassScriptPhysician profile
Carol Kashefi
NPI 1710033246
$2,893.42
in general payments reported to CMS, 2019-2025
27 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $400 · 2021: $224 · 2022: $388 · 2023: $193 · 2024: $221 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $551.28 | 2019-2020 | |
| Abbvie INC. | $402.40 | 2021-2025 | |
| Astellas Pharma US INC | $272.63 | 2019-2021 | |
| Pfizer INC. | $190.84 | 2019-2024 | |
| Medtronic, INC. | $166.46 | 2021-2024 | Interstim |
| Allergan, INC. | $141.48 | 2019 | |
| Progenics Pharmaceuticals, INC. | $124.58 | 2022 | |
| Coloplast Corp | $114.28 | 2021-2023 | Speedicath |
| Boston Scientific Corporation | $104.31 | 2019-2025 | Rezum Generator |
| Endo Pharmaceuticals INC. | $104.02 | 2019-2020 | |
| Neotract INC. | $87.29 | 2019-2020 | |
| Karl Storz Endoscopy-America | $82.46 | 2019 | |
| Urovant Sciences INC | $77.53 | 2022 | |
| Janssen Biotech, INC. | $76.99 | 2019 | |
| Antares Pharma, INC. | $63.16 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $61.92 | 2023-2025 | Gemtesa |
| Ferring Pharmaceuticals INC. | $39.61 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $37.34 | 2022 | |
| Axonics, INC. | $35.75 | 2020-2021 | |
| Duchesnay USA Incorporated | $29.08 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $25.25 | 2020 | |
| Dendreon Pharmaceuticals LLC | $22.22 | 2019 | |
| Myriad Genetic Laboratories, INC. | $19.93 | 2023 | Prolaris |
| Richard Wolf Medical Instruments Corp. | $18.99 | 2019 | |
| 180 Medical, INC. | $18.28 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $13.33 | 2019 | |
| Urogen Pharma, INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Kashefi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.